Laying the Foundation for an Improved HR+/ HER2- Breast Cancer Treatment Paradigm

Investigators continue to evaluate HER2 expression as well as CDK4/6 inhibitor use for hormone receptor–positive/HER2-negative breast cancer.

Related Keywords

Boston ,Massachusetts ,United States ,Pennsylvania ,Dana Farber Cancer Institute ,North Carolina ,Saram Tolaney ,Adamm Brufsky ,Aditya Bardia ,Susanf Smith Center ,University Of Pittsburgh School Medicine ,Medicine At Harvard Medical School ,Harvard Medical School ,Duke Cancer Institute In Durham ,Division Of Breast Oncology ,Breast Cancer Center ,Division Of Hematology Oncology ,Breast Cancer Research Program At Massachusetts ,Enhertu At Dana Farber Cancer Institute ,University Of Pittsburgh Cancer Institute ,Antonio Breast Cancer Symposium ,Breast Cancer Research Program ,Massachusetts General Hospital ,Pittsburgh School ,Clinical Investigation ,Comprehensive Breast Cancer Center ,Pittsburgh Cancer Institute ,Data May Inform Treatment ,Duke Cancer Institute ,Breast Oncology ,Harvard Medical ,Breast Cancer ,Hr Her2 ,D ,Bph ,Cdk 4 6 ,Pikc3a ,